



Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

May 4, 2026

Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydration, and bowel health

Expansion builds on Jaguar's focus on sustainably derived, plant-based gastrointestinal products for people and animals

SAN FRANCISCO, CA / [ACCESS Newswire](#) / May 4, 2026 / [Jaguar Health, Inc. \(NASDAQ:JAGX\)](#) ("Jaguar") today announced the planned launch of Neonorm Dog, a new extension of the Company's Neonorm franchise for companion animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool formation, gut hydration, and bowel health in dogs. The Neonorm franchise currently includes Neonorm Foal and Neonorm Calf, plant-based products developed to support proper hydration and bowel health in pre-weaned foals and calves. Neonorm products contain a standardized botanical extract derived from the sustainably harvested *Croton lechleri* tree, act locally in the gut.

"We believe Neonorm Dog represents a natural and strategically important expansion of the Neonorm franchise," said Lisa Conte, Jaguar's founder, president, and CEO. *"Dog owners are increasingly seeking products that are plant-based, non-antibiotic, and easy to incorporate into the management of digestive health. With Neonorm Dog, we expect to make the benefits of the Neonorm platform available to a much broader group of animals and pet owners."*

Jaguar's animal health strategy is focused on gastrointestinal products for companion and production animals. The Company's prescription animal health product Canalevia-CA1 is conditionally approved by FDA for the treatment of chemotherapy-induced diarrhea in dogs, and Jaguar recently announced statistically significant topline results from an effectiveness trial of crofelemer for treatment of chemotherapy-induced diarrhea in dogs, which the Company expects to support its advancement toward full FDA approval.

The launch of Neonorm Dog is intended to broaden Jaguar's commercial footprint in the companion animal market and extend consumer awareness of the Neonorm brand. Dogs represent one of the largest companion animal populations in the United States and Europe, and Jaguar believes Neonorm Dog may create an opportunity to reach pet owners, veterinarians, and animal health retailers seeking non-antibiotic, plant-based options to support digestive health.

"Expanding Neonorm into dogs is consistent with Jaguar's broader commercial strategy: leverage our botanical gastrointestinal expertise across clearly defined markets where hydration, stool quality, and gut health matter," said Conte. *"We believe Neonorm Dog has the potential to become an important addition to the Neonorm family and to increase awareness of Jaguar's animal health platform."*

Neonorm Dog is expected to be made available through select online and animal health retail channels as the company completes final packaging, labeling, and commercial launch preparations.

About Neonorm

Neonorm is Jaguar's non-prescription animal-health franchise of plant-based products developed to support digestive health, hydration, and normal stool quality in animals. Existing Neonorm products include Neonorm Foal and Neonorm Calf. Neonorm Dog is not intended to diagnose, treat, cure, or prevent any disease and is not intended as a substitute for veterinary care.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel, proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit <https://jaguar.health>

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements related to Jaguar launching **Neonorm Dog**. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

[press release](#)